Multiple myeloma patients who have received at least 1 prior therapy & have demonstrated disease progression on the last therapy. Patients w/ mantle cell lymphoma who have received at least 1 prior therapy.
Dosage/Direction for Use
IV 1.3 mg/m2 as 3-5 sec bolus inj twice wkly for 2 wk (day 1, 4, 8 & 11) followed by 10-day rest period (day 12-21).
Patients w/ a confirmed complete response is recommended to receive 2 additional cycles beyond a confirmation. Responding patients who do not achieve a complete remission receive a total of 8 cycles of therapy.